elaborated in partnership between Representative Mara Gabrili and the Schizophrenia Program at Universidade Federal de Sã o Paulo (UNIFESP), recommended coverage for people with psychosocial disabilities in a social inclusion program, designed to integrate this group into the job market in the state of São Paulo, Brazil. It is exciting to know that some of the WHO goals regarding mental illness are being accomplished in Brazil; however, what is the real picture of schizophrenia in our country?
Few studies have examined the prevalence of schizophrenia in Brazil, and the majority of these were conducted more than 10 years ago. Based on these studies, 4-7 the population-wide prevalence of schizophrenia in Brazil is estimated at about 0.8%. This would correspond to more than 1.6 million people in Brazil currently living with schizophrenia. 8 In this context, one study conducted in Brazil showed that the majority of patients with schizophrenia (81.5%) were allocated to the public health sector and 71.0% of them did not receive regular treatment.
This figure is very alarming; more than 900,000 of the 1.6 million individuals with schizophrenia in the public system do not receive minimally satisfactory treatment. Where are these improperly treated individuals? The answer to this question seems complex, and, indeed, we do not know. Some reach emergency rooms, receive treatment for psychotic episodes, and are then discharged. How many of these individuals receive treatment for relapse prevention? Except for those who enter the few schizophrenia programs available in some outpatient settings, the majority of these individuals do not follow treatment and become lost in the health system.
It is worth noting that relapse rates can reach up to 80.0% after 12 months without pharmacological treatment for patients after the first psychotic episode. 9 Indeed, the probability of relapse is significantly higher in those partially adherent to medication, even with effective treatment in the years preceding interruption. 10 It is known that roughly half of all individuals with schizophrenia in Brazil do not adhere to antipsychotic medication. 11 In this scenario, a powerful tool for managing medication nonadherence is the use of long-acting injectable antipsychotics, which may result in better control of adherence, thus reducing relapse rates. The adoption of this clinical practice is highly recommended for patients who do not adhere to antipsychotic treatment, and second-generation injectables are currently suggested as maintenance treatment, even after a recent episode. 12, 13 The distance between the ''optimal'' and the ''real'' scenario should be at least somewhat reduced. We recognize that the challenge is huge, as there are many barriers to overcome, from stigma to cultural and demographic boundaries. However, we should not be passive in our response to this situation, waiting for patients to knock on our doors asking for assistance. Simple attitudes, such as active case search, psychoeducational support groups for families and patients, welltrained psychiatrists, and multidisciplinary approaches, can support a better prognosis for these patients and change current outcomes in schizophrenia.
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